LUNG (Pulmonx) Beta: 0.9600 (As of Jun. 25, 2026)


LUNG Pulmonx Corp LUNG
49 GF Score
Price $1.39
GF Value $7.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pulmonx Beta?

Pulmonx LUNG +8.17% 49 Beta is 0.9600 as of Jun. 25, 2026. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Pulmonx's Beta is 0.9600.


Pulmonx  (NAS:LUNG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Pulmonx Beta Related Terms


Pulmonx Beta Historical Data

* Premium members only.

The historical data trend for Pulmonx's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmonx Beta Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.38 0.23 0.44

Pulmonx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 -0.37 -0.85 0.44 0.83

LUNG vs LNSR, QTI, MDAI: Beta Comparison

For the Medical Devices subindustry, Pulmonx's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmonx Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Beta distribution charts can be found below:

* The bar in red indicates where Pulmonx's Beta falls into.


LUNG
49GF Score
Pulmonx Corp LUNG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmonx Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.9600 mean?
Pulmonx (LUNG) has a Beta of 0.9600 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pulmonx and its competitors.
Is Pulmonx's Beta too high?
Pulmonx's current Beta is 0.9600. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Beta compare to LNSR and QTI?
Pulmonx's Beta of 0.9600 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pulmonx and its competitors. Pulmonx's current Beta is 0.9600. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.39 — trading 80.5% below its estimated fair value. The current Beta is 0.9600. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pulmonx (LUNG), the current Beta is 0.9600 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $1.39 is trading 80.5% below its estimated GF Value™ of $7.13. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

  • Beta: 0.9600
  • GF Value™: $7.13 vs. price of $1.39 (80.5% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pulmonx Business Description

Other Exchanges 4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score

Get the complete analysis for LUNG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$7.13
GF Value